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Aurora kinases in childhood acute leukemia: the promise of
aurora B as therapeutic target
SA Hartsink-Segers1,2, CM Zwaan1, C Exalto1, MWJ Luijendijk1, VS Calvert3, EF Petricoin3, WE Evans4, D Reinhardt5, V de Haas6,
M Hedtja¨rn7, BR Hansen7, T Koch7, HN Caron2,8, R Pieters1,6 and ML Den Boer1,2,6
We investigated the effects of targeting the mitotic regulators aurora kinase A and B in pediatric acute lymphoblastic leukemia (ALL)
and acute myeloid leukemia (AML). Aurora protein expression levels in pediatric ALL and AML patient samples were determined by
western blot and reverse phase protein array. Both kinases were overexpressed in ALL and AML patients (Po0.0002), especially in
E2A-PBX1-translocated ALL cases (Po0.002), compared with normal bone-marrow mononuclear cells. Aurora kinase expression was
silenced in leukemic cell lines using short hairpin RNAs and locked nucleic acid-based mRNA antagonists. Aurora B knockdown
resulted in proliferation arrest and apoptosis, whereas aurora A knockdown caused no or only minor growth delay. Most tested cell
lines were highly sensitive to the AURKB-selective inhibitor barasertib–hydroxyquinazoline–pyrazol–anilide (AZD1152-HQPA) in the
nanomolar range, as tested with an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
assay. But most importantly, primary ALL cells with a high aurora B protein expression, especially E2A-PBX1-positive cases, were
sensitive as well. In adult AML early clinical trials, clear responses are observed with barasertib. Here we show that inhibition of aurora
B, more than aurora A, has an antiproliferative and pro-apoptotic effect on acute leukemia cells, indicating that particularly targeting
aurora B may offer a new strategy to treat pediatric ALL and AML.
Leukemia (2013) 27, 560–568; doi:10.1038/leu.2012.256
Keywords: aurora kinase; pediatric acute leukemia; AZD1152; LNA-oligonucleotide; gene silencing; targeted therapy
INTRODUCTION
Acute leukemia accounts for approximately 30% of all pediatric
cancers and is therefore the most common type of cancer in
children. In approximately 85% of the cases, acute lymphoblastic
leukemia (ALL) is diagnosed, in 15% acute myeloid leukemia
(AML). Over the past decades, clinical outcome of pediatric acute
leukemia has improved toward 5-year event-free survival rates of
80% for ALL and 60–70% for AML by the use of multiagent
chemotherapy.1,2 Targeting leukemia-speciﬁc molecular abnorma-
lities may help further improve outcome and reduce adverse side
effects of therapy.
Promising targets in this respect may be the members of the
aurora kinase (AURK) family, which consists of three serine/
threonine kinases: aurora A, B and C, encoded by the AURKA,
AURKB and AURKC genes, respectively. Although aurora C is mainly
expressed in the testis and associated with male fertility and
meiosis, aurora A and B are both important regulators of mitosis.
Despite sharing 71% identity in their C-terminal catalytic domains,
aurora A and B have a different subcellular localization and
perform essential and distinct functions during different phases of
the cell cycle. Aurora A is active during late S and early G2 phase,
localizing to the centrosomes and spindle poles, and ensuring
proper spindle assembly and chromosome alignment during
mitosis. Throughout G2, aurora B functions in a protein complex,
mainly associating with microtubules near the kinetochores, and is
responsible for bipolar attachment of the spindle to the
centromeres and correct segregation of the daughter chromatids.
Subsequently, aurora B redistributes to the midbody where it has
a key role in cytokinesis.3,4
Aberrant expression of aurora A and B is associated with
chromosomal instability and dysfunctional cell division. Not surpris-
ingly, ampliﬁcation and overexpression of aurora kinases A and B are
associated with tumorigenesis. Both aurora A and B are overexpressed
in a large number of human solid tumors as well as leukemia cell lines
and adult AML patients,5 also showing a correlation with a poor
prognosis in these patients.6,7 The clinical value of aurora A and B
expression in adult ALL and in pediatric leukemias is still unknown.
Several small-molecule inhibitors of aurora kinases induce
apoptosis in cancer cell lines in vitro and in vivo. Hesperadin,
ZM447439 and VX-680 (also known as MK-0457 or tozasertib)8–10
were among the ﬁrst aurora kinase inhibitors to be described.
VX-680, a pan-aurora inhibitor, was the ﬁrst to show antitumor
activity in vivo,10 but clinical trials were terminated because of side
effects. Trials are currently ongoing for several aurora A- and
B-selective inhibitors, among which are the second-generation
aurora A-selective inhibitor MLN8237 (alisertib) and the aurora
B-selective compound barasertib (AZD1152) (www.clinicaltrials.
gov). Barasertib induces apoptosis in xenograft models of several
cancer types, including lung, colon and AML.11 Phase I/II clinical
trials in adult AML show that barasertib has the ability to produce
complete responses in relapsed/refractory and treatment-naive
newly diagnosed elderly patients.12–14
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Although adult studies are numerous, only few studies address
the efﬁcacy of aurora kinase inhibition in the treatment of
childhood acute leukemia and no inhibitor has entered the clinic
yet. To determine the potential of aurora A and B as a target for
therapy, we investigated the expression of both kinases in large
series of childhood ALL and AML patients and studied the effects
of silencing these genes in these malignancies. Our study
demonstrates that inhibition of aurora B in particular may be
effective for the treatment of childhood acute leukemia.
MATERIALS AND METHODS
More detailed descriptions of the Materials and Methods used are included
as Supplementary Information on the Leukemia website.
Cell-line culture
Cell lines were purchased from DSMZ (Braunschweig, Germany) and
cultured in Roswell Park Memorial Institute mediumþ glutamax (Gibco
BRL, Life Technologies, Bleiswijk, The Netherlands) (leukemia cell lines) or
Dulbecco’s Modiﬁed Eagle’s mediumþglutamax (Gibco BRL, Life Technolo-
gies) (HEK293T) supplemented with pen-strep (Gibco BRL, Life Technologies),
fungizone (Gibco BRL, Life Technologies) and 10 or 20% fetal calf serum
(Integro, Zaandam, The Netherlands). Cells were cultured in a humidiﬁed
37 1C incubator, with 5% CO2. RNA was isolated with an RNeasy minikit
(Qiagen, Venlo, The Netherlands) according to the manufacturer’s protocol.
Patient samples
Bone marrow (BM) or peripheral blood samples from children with newly
diagnosed ALL (n¼ 521) and AML (n¼ 237), and from children with no
hematological disorder (normal BM (nBM)) (n¼ 18), were processed as
described in the Supplementary Information. Written informed consent
was obtained from patients and/or parents/guardians to use excess of
diagnostic material for research purpose, as approved by the institutional
review boards.
Gene-expression arrays and normalization
RNA was extracted from patient samples with TRIzol reagent (Invitrogen,
Life Technologies, Breda, The Netherlands) according to the manufacturer’s
protocol and gene expression analyzed by Affymetrix U133 GeneChips
version A or plus 2.0 (Santa Clara, CA, USA). The original data ﬁles have
been deposited in the Gene Expression Omnibus database (accession no.
GSE13351, GSE13425 and GSE17855). Using the probe sets common to
both chips, the data sets of ALL (n¼ 297), AML (n¼ 237) and nBM (n¼ 8)
were normalized together using robust multichip average and variance
stabilizing normalization 2. Batch effects were corrected for by applying
the ComBat procedure. AURKA, B and C were represented by probe sets
204092_s_at, 209464_at, and 211107_s_at, respectively. There was a good
correlation between results obtained by gene-expression array and reverse
transcription quantitative real-time PCR (rs¼ 0.77 and Po0.0001;
Supplementary Figure 1).
Lentiviral infections
pLKO.1 Mission short hairpin RNA (shRNA) vectors SHC002 (nonsilencing
control vector), SHC005 (against eGFP), TRCN0000000655 (against AURKA)
and TRCN0000000776 (against AURKB), containing a puromycin selection
marker, were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands). Leukemia cell lines were spin-infected with a multiplicity of
infection of 2.5 in the presence of polybrene (Sigma-Aldrich) and cultured
for 24 h before selection on puromycin (Sigma-Aldrich). Cell viability was
determined with a trypan blue exclusion assay.
Locked nucleic acid (LNA)-oligonucleotide (LNA-oligo)
transfections
Cell lines were cultured in the presence of 10 mM LNA-oligos against AURKA
(SPC5587), AURKB (SPC5549), a scrambled control oligo (SPC3088) or
control medium only. Unassisted uptake of oligos (‘gymnosis’) after 48 h
was assessed using a 6-carboxyﬂuorescein (FAM)-labeled LNA-oligo
(SPC5059). Cytospins of transfected cells were stained with vectashield
4’,6-diamidino-2-phenylindole (DAPI) and analyzed with ﬂuorescent
microscopy. Cell viability was determined with a trypan blue exclusion test.
In vitro MTS assay for drug sensitivity
Cells were plated at a concentration of 0.2–1 106 cells per ml in triplicate
(cell lines) or 1.6 106 per ml in duplicate (primary cells) and exposed to
doses of barasertib–hydroxyquinazoline–pyrazol–anilide (Barasertib-HQPA;
AstraZeneca, Cheshire, UK), PHA-739358 (danusertib; Selleck Chemicals,
Munich, Germany), MLN8237 (Alisertib; Selleck Chemicals) or VX-680 (tozasertib;
LC Laboratories, Woburn, MA, USA) ranging 1nM–20mM. Cells were incubated
with MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium; Promega, Madison, WI, USA) and PMS (phenazine
methosulfate; Sigma-Aldrich) after 72 h for 3 h (cell lines) or after 96 h for
4 h (primary cells), and absorbance was quantiﬁed at l¼ 490 nm on a
VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Protein electrophoresis and western blot
A total of 20mg of protein was loaded onto gel and blotted onto
nitrocellulose (Schleicher & Schuell, Dassel, Germany). Primary antibodies
were from AbD Serotec (Kidlington, UK) (aurora A, no. MCA2249), Cell
Signaling Technology (Danvers, MA, USA) (aurora B, no. 3094; cleaved poly
(ADP-ribose) polymerase (PARP), no. 9541; glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), no. 2118) and Abcam (Cambridge, UK) (b-actin,
ab6276). Proteins were detected with either an horseradish peroxidase-
tagged secondary antibody (Cell Signaling Technology) and scanned with a
Syngene Chemigenius (Cambridge, UK) or detected with a ﬂuorescently
labeled secondary IRDye antibody (LI-COR Biosciences, Lincoln, NE, USA)
and scanned with an Odyssey Infrared Imaging System (LI-COR Biosciences).
Signals were digitally quantiﬁed with subtraction of background.
Reverse phase protein array
Lysates of 172 pediatric ALL patient samples and 10 nBM samples were
spotted twice in triplicate on glass-backed nitrocellulose-coated array
slides (FAST slides; Whatman Plc, Kent, UK). The slides were stained with an
aurora A (Abd Serotec; no. MCA2249) or aurora B (Cell Signaling
Technology; no. 3094) antibody, followed by incubation with a biotinylated
secondary antibody. Slides were scanned using a NovaRay CCD ﬂuorescent
scanner (Alpha Innotech, San Leandro, CA, USA). Protein levels were
calculated relative to the total amount of protein per sample.
Statistical analyses
The nonparametric Mann–Whitney U-test was applied to compare
expression levels between patient groups. Signiﬁcance of correlation
between the gene-expression array data and reverse transcription
quantitative real-time PCR data, and between expression levels and drug
sensitivity, was determined with a Spearman’s rank correlation test. Cell-
cycle distribution proportions of replicate experiments were compared with
a paired Student’s t-test. Po0.05 was considered statistically signiﬁcant.
RESULTS
Aurora A and B proteins are overexpressed in pediatric ALL and
AML cases
At the mRNA level, AURKA, AURKB and AURKC levels did not
signiﬁcantly differ between leukemic cells of patients and normal
BM cells of healthy children (Figures 1a–c), but AURKA was
differentially expressed in T-ALL patients (Po0.0001) and AURKB
both in T-ALL (Po0.0001) and E2A-PBX1 patients (P¼ 0.0008)
compared with (other) precursor B-ALL patients (Figures 1a and b).
Because aurora C is believed to have a role mainly in meiosis in the
testis, we further focused on the role of aurora A and B in leukemia.
At the protein level, aurora A was 1.9-fold more highly expressed
in ALL than in nBM (P¼ 0.0002; Figure 1d) and expression levels in
ALL and AML cases were comparable (Figure 1e; see Supplementary
Figure 2 for original blots). Elevated protein expression of aurora B
in leukemic cells was even more striking because seven out of ten
nBM samples did not express aurora B protein at all (Po0.0001;
Figure 1f) and both ALL and AML cases had detectable protein
levels more often than nBM (Figures 1f and g). Remarkably, protein
expression levels of aurora A and especially aurora B were higher in
precursor B-ALL cases with an E2A-PBX1 translocation than in cases
without this translocation: 1.2 fold (P¼ 0.002; Figure 1d) and 1.8 fold
(Po0.0001; Figure 1f), respectively. No difference was seen between
other genetic subtypes of ALL.
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The differential expression of aurora B in ALL was not likely
caused by ampliﬁcation or deletion of the AURKB gene, as array
comparative genomic hybridization analysis of 49 precursor B-ALL
and 87 T-ALL patients did not reveal any aberrations speciﬁc for
any of the three aurora genes (Supplementary Information and
Supplementary Figure 3).
shRNA-mediated silencing of AURKB in ALL and AML results in
inhibition of cell growth and apoptosis
The expression of AURKA and AURKB was silenced in ﬁve pediatric
and one adolescent leukemic cell line (NB-4) using shRNAs.
Nontargeting control shRNAs were used as a control for infection
and off-target RNA interference effects.
Aurora A protein levels were reduced within 96 h by at least
47% (THP-1) and up to 97% (JURKAT), and aurora B protein
levels by 69% (THP-1) up to 96% (JURKAT) (Figure 2; left panels).
In all cell lines, knockdown of aurora B clearly affected cell
growth by growth arrest and/or induction of apoptosis (Figure 2;
middle panels). Cleaved PARP was detected in all cell lines
72 h after aurora B silencing (Supplementary Figure 4), indicating
that apoptosis was initiated. Aurora A silencing did not affect
or only moderately affected cell growth (Figure 2; middle
panels).
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Figure 1. Expression patterns of aurora A, B and C in ALL and AML patients and nBM mononuclear cells. Gene expression of AURKA (a), AURKB
(b) and AURKC (c) in genetic subtypes of ALL cases (n¼ 297), AML cases (n¼ 237) and nBM samples (n¼ 8) was analyzed by gene-expression
array. Asterisks indicate statistical significance with Po0.01 of nBM vs ALL or AML, T-ALL vs precursor B-ALL, and cytogenetic subtypes of
precursor B-ALL or AML vs all other subtypes of the B-lymphoid or myeloid lineage. Reverse phase protein arrays (RPPAs) were performed for
ALL (n¼ 172) and nBM (n¼ 10) samples to measure aurora A (d) and aurora B (f ) protein levels. Values were corrected for total protein and
background signals. Statistical significance was determined by comparing groups to all (other) ALL patients. Additionally, protein levels of
aurora A (e) and aurora B (g) in ALL (n¼ 10) and AML (n¼ 14) samples were quantified with western blot analysis and corrected for total
protein loading by GAPDH expression. Horizontal bars indicate median values. nBM, normal BM mononuclear cells.
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In line with the modest phenotypic effects of aurora A
knockdown on cell proliferation, no profound effect on cell-cycle
distribution was observed after 72 h of aurora A silencing. In
contrast, we observed various cell-cycle effects of aurora B
knockdown (Figure 2; right panels). In JURKAT, a tetraploid cell
line, silencing of aurora B resulted in a small population of 8N cells,
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containing a double amount of DNA. In the other cell lines, cells
tended to accumulate in the apoptotic sub-G0/G1 phase (697,
MV4;11, NB-4 and THP-1) and/or in the G2/M phase (REH, JURKAT
and THP-1), but not in the G1 or S phase. This is in correspondence
with the function of aurora B in the spindle checkpoint during the
metaphase of the cell cycle and suggests that some cell lines
accumulate in G2/M upon loss of aurora B, whereas others
become apoptotic and may leave the cell cycle at any stage.
Effects of LNA-based mRNA antagonists of AURKA or B are
comparable to silencing by shRNAs
Next, we silenced AURKA or AURKB expression using target-speciﬁc
LNA-based mRNA antagonists (LNA-oligos). Transfection of a
ﬂuorescently labeled LNA-oligo showed that these oligonucleo-
tides efﬁciently accumulate in cell lines within 48 h (Figure 3a).
LNA-oligos against AURKA and AURKB decreased their target
mRNA and protein expression levels within 96 h of exposure by at
least 75% compared with a scrambled control LNA-oligo, whereas
the AURKA LNA-oligo did not decrease AURKB mRNA levels and
vice versa, conﬁrming speciﬁcity (Figure 3b). Phosphorylation of
histone H3 (Ser10), a known downstream target of aurora B, was
reduced upon AURKB but not AURKA knockdown (Supplementary
Figure 5).
ALL and AML cell lines were far more sensitive to the AURKB
LNA-oligo than to the AURKA LNA-oligo. Targeting aurora B
resulted in proliferation arrest and cell death, whereas aurora A
knockdown only led to a slight growth delay in most cell lines
(Figure 3c). This is in line with the effects observed with AURK-
speciﬁc shRNAs (Figure 2, middle panels). Knocking down both
aurora A and B simultaneously did not additively or synergistically
reduce growth compared with silencing of aurora B only
(Figure 3d). These ﬁndings suggest that aurora B may be a more
relevant target in pediatric ALL and AML than aurora A.
Cell lines and patients with a high aurora B expression tend to be
sensitive to barasertib-HQPA
We compared the efﬁcacy of the pan-aurora kinase inhibitors VX-
680 and danusertib, aurora A-selective inhibitor MLN8237 and
aurora B-selective inhibitor barasertib-HQPA (the more active
metabolite of barasertib) in REH, 697 and NALM-6 (ALL) and
MV4;11 (AML). All compounds inhibited cell growth when used in
concentrations in the low to mid-nanomolar range, with cell lines
being comparably sensitive to VX-680, MLN8237 and barasertib-
HQPA, and relatively resistant to danusertib (Supplementary
Figure 6). Because silencing experiments with shRNA and LNA
mRNA antagonists identiﬁed aurora B as suitable target, the
efﬁcacy of aurora B-selective barasertib-HQPA was tested in a
range of ALL and AML cell lines. Exposure to barasertib-HQPA
induced a phenotype typically associated with aurora B inhibition:
cells accumulated in G2/M phase or sub-G0/G1 phase similarly to
observations made upon silencing with shAURKB (Supplementary
Figure 7a). In addition, phosphorylation of histone H3 (Ser10) was
reduced (Supplementary Figure 7B). Eighteen out of twenty cell
lines tested were equally sensitive to growth inhibition by
barasertib-HQPA in the nanomolar range (GI50¼ 19–233 nM;
median 65 nM) (Figure 4a). Only JURKAT (T-ALL) and THP-1 (MLL-
rearranged AML) were highly resistant to this drug, with GI50
values in the micromolar range (8.4 and 16 mM, respectively). There
was no correlation between sensitivity to barasertib-HQPA and
aurora B mRNA or protein levels.
We next exposed eight primary ALL patient samples with a high
aurora B protein expression and eight with a low expression to
barasertib-HQPA in vitro. Cell survival reversely correlated with
aurora B protein expression level (rs¼  0.532 and P¼ 0.034;
Figure 4b); patient samples with a high aurora B expression were
more sensitive to barasertib-HQPA than those with a low
expression (P¼ 0.046; Figure 4c). The most sensitive patient
samples comprised two E2A-PBX1-translocated cases, a hyperdi-
ploid and a karyotypically normal case, but E2A-PBX1-positive cells
appeared to be more sensitive (P¼ 0.037) than samples without
this translocation (Figure 4c and Supplementary Figure 8).
DISCUSSION
With leukemia being the most prevalent of cancers among
children, and the medical world striving to improve clinical
outcome achieved with the current treatment strategies and
reduce long-term side effects among cancer survivors, there is a
great medical need to improve therapy options for children with
ALL or AML. This study aimed to investigate aurora kinases A and
B as potential therapeutic targets for the treatment of childhood
ALL and AML, and has shown that (1) aurora B, more so than
aurora A, is an essential protein for proliferation and survival of
acute leukemia cells, (2) both ALL and AML cell lines are sensitive
to AURKB LNA-oligos and the aurora B-selective inhibitor
barasertib-HQPA in vitro and (3) primary ALL patient samples
with high protein levels of aurora B are more sensitive to
barasertib-HQPA than those with low expression of aurora B.
Of the three aurora kinase family members A, B and C, most
studies have focused their attention on aurora A, showing its
relevance to oncogenesis. Surprisingly, our ﬁndings indicate that
aurora A is of less importance in childhood ALL and AML than
aurora B. First, the difference in aurora A protein expression levels
between acute leukemia patients and healthy controls was not as
profound as that of aurora B. This is also the case in adult ALL,
where only some patients express aurora A and only at a low level
compared with adult AML.5 Second, compared with aurora B
inhibition, we observed no or a delayed phenotypic effect of
aurora A inhibition in acute leukemia cell lines, as shown by
normal cell-cycle distribution and modest effects on cell
proliferation. Taken together, these results suggest that aurora A
is functionally less signiﬁcant for pediatric acute leukemia cells
and may therefore be a less likely choice as target for therapy. This
is in contrast to many adult and pediatric solid tumors as well as
adult AML,5,15 in which aurora A is aberrantly expressed and a
promising target for treatment as shown by many in vitro and
in vivo inhibitor studies (reviewed by Dar et al.16). Interestingly
though, our cell lines seem equally sensitive to growth-inhibitory
effects of the aurora A-inhibitor MLN8237 and aurora B-inhibitor
barasertib-HQPA, and Maris et al.17 recently achieved tumor
reduction with MLN8237 in murine xenograft models for pediatric
ALL. It is known that the methodological differences between a
small-molecule kinase inhibitor and RNA interference can cause
different phenotypic effects. The former is usually directed against
the kinase function of the protein, whereas the latter also
Figure 2. Effect of short hairpin-mediated aurora A or B silencing in ALL and AML cell lines. Left panels show western blot analysis of aurora A
or B knockdown in three ALL and three AML cell lines, respectively: REH (a), 697 (b), JURKAT (c), MV4;11 (d), NB-4 (e) and THP-1 (f ). Brightness
and contrast of images was optimized and dotted lines indicate where separated samples from the same gel were grouped. Blots are
representative of multiple independent experiments. Middle panels show the effect of aurora A and B silencing on cell growth. For a–e,
graphs present the mean of multiple experiments and error bars indicate one side of the s.e. of the mean. Right panels present effects on cell-
cycle distribution measured by flow-cytometry analysis of propidium iodide incorporation after 72 h of aurora kinase knockdown. NTC,
nontargeting control short hairpin; sh/shAURK, short hairpin against AURK.
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Figure 3. The in vitro efficacy of AURK-targeting LNA-oligos in ALL and AML cell lines. Cells were incubated with 10 mM of LNA-oligos
complementary to AURKA or AURKB or a scrambled control. (a) Microscopic fluorescent imaging of the uptake of a FAM-labeled LNA-oligo by
ALL (left) and AML cell lines (right) after 48 h of exposure. Nuclei were stained blue with DAPI. FAM is depicted in green. Bars represent 25 mm.
(b) Target-specific reduction of aurora A (left) and aurora B (right) mRNA (upper panels) and protein (lower panels) after exposure of REH cells
to an AURKA, AURKB or scrambled control LNA-oligo. Gene expression was determined relative to housekeeping gene RPS20 and was set at
100% for scrambled controls. Brightness and contrast of protein images was optimized and dotted lines indicate where separated samples
from the same gel were grouped. (c) Effects of LNA-mediated aurora A or B knockdown on growth of ALL (left) and AML cell lines (right). (d)
Effect on cell growth of simultaneous aurora A and B knockdown by LNA-oligos. REH (ALL) and MV4;11 (AML) were incubated for 96 h with
5mM LNA-oligos targeting AURKA and/or 5 mM LNA-oligos targeting AURKB. Cell growth was determined by trypan blue exclusion and
expressed as a percentage of the cell count upon incubation with an equal concentration of a scrambled nontargeting LNA-oligo. AA, LNA-
oligo targeting AURKA; AB, LNA-oligo targeting AURKB; scr, scrambled nontargeting LNA-oligo.
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interferes with the architecture of protein complexes where the
target takes part in.18 This functional difference may explain why
aurora A-targeting drugs do seem to have clinical potential in
childhood leukemia, whereas our study shows that silencing of
AURKA expression has only a minor impact on leukemic cell lines
compared with AURKB silencing.
A nonredundant role for aurora B in maintenance of the
leukemic cell is supported by our ﬁndings that knocking down
AURKB results in inhibition of cell growth and apoptosis in our cell-
line models. Although some cell lines accumulate in mitotic state,
polyploidy is not observed for most. Indeed, it has been described
that, perhaps among other contributing factors, the p53 and p73
status of cells may determine whether aurora B inhibition leads to
polyploidy or cell-cycle arrest and apoptosis.18,19 We showed that
most leukemic cell lines in this study are sensitive to low
concentrations of barasertib-HQPA and that this sensitivity does
not seem to correlate with aurora B expression. This is consistent
with previous studies in AML cell lines.20–22 Two out of twenty
tested cell lines, JURKAT and THP-1, are relatively resistant to
barasertib-HQPA, although functional studies with shRNAs and
LNA-oligos in these cell lines clearly show an antiproliferative
effect of AURKB silencing. These two discordant cell lines have in
common that they are tetraploid, in contrast to the other cell lines
tested. This might render the barasertib-HQPA compound less
toxic in these two cell lines. In addition, barasertib-HQPA may
induce senescence rather than being toxic to these cell lines, as
recently being shown for THP-1 by Oke et al.22 This again
illustrates the potentially different phenotypic effects of small-
molecule inhibitors and RNA interference.
Similarly to adult solid tumors23–27 and adult acute leukemias,5
we show that aurora B protein is overexpressed in pediatric acute
leukemia and that primary pediatric leukemia samples display a
differential sensitivity to barasertib-HQPA in vitro, which correlates
with aurora B expression levels. In this respect, the high aurora B
protein expression in precursor B-ALL cells with an E2A-PBX1
translocation is of special interest, for it may indicate that E2A-
PBX1-positive patients may beneﬁt even more from aurora B
inhibition. Indeed, silencing of aurora B induced cell death most
rapidly in 697 cells, carrying the E2A-PBX1 translocation
(Figure 2b), and E2A-PBX1-positive primary cells, which highly
expressed aurora B protein, seemed to be more sensitive to
barasertib-HQPA (Figure 4c). A direct relation between the
presence of the E2A-PBX1 fusion protein and elevated expression
of aurora B has not been established at this point but deﬁnitely
warrants further investigation. Nonetheless, extrapolating the
differential sensitivity of primary patient samples to barasertib-
HQPA to the in vivo situation would suggest that barasertib could
effectively target leukemic cells of a group of patients including
but not limited to E2A-PBX1-translocated ALL cases.
The differential aurora B protein expression between leukemic
cells and normal BM cells that we show in this study may offer a
therapeutic advantage when a targeted drug is aurora B-speciﬁc.
Phase I and II clinical trials currently address the toxicity and
efﬁcacy of the aurora B-selective inhibitor barasertib in adult solid
10 Precursor B-ALL:
MLL-rearranged
TEL-AML1
69
7
0.01
0.1
1
AML:
hyperdiploid
E2A-PBX1
BCR-ABL1
normal karyotype
T-ALL
G
I5
0 
(M
)
BE
L-1
KO
PN
-8
SE
M
RE
H
MH
H-
CA
LL
-2
MH
H-
CA
LL
-3
SU
P-B
15
TO
M-
1
MH
H-
CA
LL
-4
HP
B-
AL
L
LO
UC
Y
MO
LT
-16
JU
RK
AT
KA
SU
MI
-1
NB
-4
TH
P-1
MV
4;1
1
NO
MO
-1
SH
I-1 AML1-ETO
PML-RARα
MLL-rearranged
*
80
100
80
100
0 5000 10000 15000
0
20
40
60
rs=0.53
p=0.034
normalized Aurora B protein expression
le
uk
em
ic
 c
el
l v
ia
bi
lit
y 
(%
)
0
20
40
60
* p=0.046le
uk
em
ic
 c
el
l v
ia
bi
lit
y 
(%
)
Au
ror
a B
 lo
w
Au
ror
a B
 hi
gh
Figure 4. Sensitivity of ALL and AML cell lines and primary patient cells to barasertib-HQPA. Cell lines were exposed in triplicate for 72 h and
primary cells in duplicate for 96 h to 0.001–20mM of barasertib-HQPA. Growth or viability was determined with an MTS assay and calculated as
the percentage of live cells compared with unexposed cells. (a) Drug concentrations necessary to inhibit growth of leukemic cell lines by 50%
(GI50) within 72 h, calculated from the average of at least three experiments. Symbols represent different leukemic subtypes. The dashed
horizontal line indicates the maximum concentration tested. (b) Correlation plot between aurora B protein expression and viability of 16 ALL
patient samples when exposed to 78 nM barasertib-HQPA for 96 h. (c) Cell viability after exposure of primary leukemic samples, including E2A-
PBX1-positive cases (open triangles), with low vs high aurora B protein expression. The median aurora B protein expression of 172 patients
evaluated by RPPA was taken as a cut off for selecting cases with high and low expression for the MTS assay. Horizontal bars indicate the
median of the presented data.
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tumors and adult AML. Studies in adult patients with advanced
solid tumors were terminated because of a lack of objective tumor
response and dose-limiting toxicities like neutropenia and
leukopenia at relatively low doses.28 In contrast, studies in
relapsed and newly diagnosed adult AML patients with a very
poor prognosis reported well-tolerated doses up to 1200mg and
remarkable clinical response rates of 19–25%,12,14 or 43% in the
combination of barasertib with cytosine arabinoside.13 At the
moment, other pivotal studies in AML are underway.
Small-molecule inhibitors in general often interfere with
proteins other than their main target, increasing the chance of
side effects in clinical practice. LNA-based mRNA antagonists may
offer an alternative and more speciﬁc way to silence a gene.
Several studies have reported a clinical potential for LNA
antagonists in cancer, such as those targeting BCL-2, ERBB-3 and
HIF-1A.29–31 Three LNA-based mRNA antagonists are currently
being tested in phase I early clinical trials, one of them being EZN-
3042, an inhibitor of the aurora B-binding partner Survivin, in
children with relapsed ALL (NCT01186328). We have in this study
shown that LNA-oligos accumulate and actively silence targeted
genes in ALL and AML cells without further formulation, a process
called gymnosis.32 The phenotype obtained in vitro with gymnotic
delivery more closely mimics the situation in vivo where LNA-
based oligonucleotides have to enter cells without delivery
vehicles. Our study indicated that targeting AURKB by LNA-
based antagonists effectively induced growth arrest and apoptosis
in acute leukemia cell lines similarly to the clinically less applicable
lentiviral delivery of shRNAs. Together with the emerging clinical
opportunities of LNA-based antagonists, these data imply a
second option besides conventional small-molecule inhibitors
for addressing the therapeutic value of aurora B silencing in
children with ALL and AML.
In conclusion, there is a great therapeutic potential for aurora
kinase inhibition in childhood acute leukemia. Moreover, we have
shown that downregulation of AURKB expression targets pediatric
ALL and AML more effectively than downregulation of AURKA.
Contributing to the constant search for alternative therapies that
improve long-term clinical outcome and reduce side effects of
treatment, these ﬁndings offer a rationale for focusing on aurora
B-targeting strategies in the treatment of children with acute
leukemia.
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